OPRX · Nasdaq · Healthcare
OptimizeRx Corporation (OPRX) — Rank #108 by gross profitability (GP/assets 0.45) · ROE 3.9% · Piotroski F-Score 8 / 9.
As-of 2026-10-30 · CIK 0001448431 · all metrics point-in-time as of the filing date.
About
OptimizeRx Corporation operates as a digital healthcare technology company.
Show moreShow less
It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers' target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, limited distribution drug information, and patient support program messaging through healthcare professionals; and media execution solutions, which deliver messages through consumer omnichannel network, including through programmatic display, programmatic connected television/over-the-top, programmatic social media, addressable television, digital out-of-home, programmatic audio, and email/direct mail. The company also offers pharmacy alerts, which flag pharmacies that have prescription medications in stock; and financial messaging solutions, which provide prescribers visibility to branded copay offers for patients directly within electronic health record systems and ePrescribing platforms.
The company was founded in 2006 and is headquartered in Waltham, Massachusetts.
- Industry
- Health Information Services
- Sector
- Healthcare
- State
- NV
- Filer Category
- Non-accelerated filerSmaller reporting company
- Fiscal Year End
- December 31
- Website
- optimizerx.com
Company Snapshot
P/E and reverse DCF are the primary valuation lenses at this stage.
Market Cap
—
P/E (annual)
—
P/S (annual)
—
P/B
—
P/OCF (annual)
—
Shareholder Yield
—
Employees
132
Industry
Health Information Services
Exchange
Nasdaq
11/12
Flags passed
OPRX passes 11/12 quality flags
1 caution to review
- CAUTIONDilution above 2%
Annual share count increase exceeds 2%. May be acceptable for high-growth companies funding talent via stock compensation
- PASSGross margin holding
- PASSFCF not negative from investment
- PASSDisclosure consistent
- PASSRevenue not declining
- PASSOperating margin holding
- PASSFree cash flow intact
- PASSPasses safety gate
- PASSBalance sheet stable
- PASSNo competitive retreat
- PASSSBC not compressing margin
- PASSNo valuation convergence
Strengths Deferred revenue growing
A count of the 12 warning flags that could be evaluated. Unweighted: colour follows the worst flag.
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
1/2 passOperating margin expansion and free cash flow are the primary reads at this stage.
Profitability
Does it make money well?
No warning flags · GP/assets 0.45
Gross profitability (GP / assets)
0.45
Primary signal (Novy-Marx).
4th of 11 SIC 7389 peers
Return on equity
3.9%
Gross margin
67.3%
3rd of 11 SIC 7389 peers
Revenue growth (YoY)
18.8%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
20.6%
Revenue CAGR (5Y)
20.4%
Earnings CAGR (3Y)
—
FCF CAGR (3Y)
20.8%
Cash Flow Health
Is the cash real?
No warning flags · FCF 264% above net income
Free cash flow
$18.66M
Operating cash flow minus capex.
Positive free cash flow
FCF vs net income
263.5%
(FCF − net income) ÷ |net income|. Positive: cash above earnings. Negative: below.
FCF not below net income
Fails when free cash flow is below net income (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
6.4%
Stock-based comp intensity.
Balance Sheet Strength
Can it survive a storm?
Caution: Dilution above 2% · net cash $5.09M, F-Score 8/9
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
0.25
1st of 10 SIC 7389 peers (best = lowest)
Current ratio
5.58×
1st of 11 SIC 7389 peers
Quick ratio
5.03×
Net cash
$5.09M
Cash & equivalents minus total debt.
Piotroski F-Score
8 / 9
Fundamental-strength score (0-9).
Valuation
Is the price reasonable?
No warning flags
Capital allocation quality
Composite score
1.3 / 5
Lifecycle Phase History
Price History
Source filings on SEC EDGAR: 10-K annual reports · 10-Q quarterly reports